Compare ATRC & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | SANA |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2005 | 2021 |
| Metric | ATRC | SANA |
|---|---|---|
| Price | $28.41 | $2.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $51.17 | $7.80 |
| AVG Volume (30 Days) | 692.6K | ★ 4.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.74 | 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,630,000.00 | N/A |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.40 | N/A |
| 52 Week Low | $25.36 | $2.43 |
| 52 Week High | $43.18 | $6.55 |
| Indicator | ATRC | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 36.32 |
| Support Level | $28.03 | N/A |
| Resistance Level | $30.49 | $3.41 |
| Average True Range (ATR) | 1.20 | 0.21 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 70.72 | 20.26 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.